BioCentury
ARTICLE | Company News

Arena, atugen technology evaluation deal

September 10, 2001 7:00 AM UTC

atugen (Berlin, Germany) will use its GeneBloc antisense platform and cellular delivery technology to down-regulate the expression of CNS gene targets supplied by ARNA. ARNA will then use the GeneBloc...